WORLD-GOVERNMENT-SUMMIT
8.3.2021 13:24:06 CET | Business Wire | Press release
The World Government Summit Dialogues will deliver 21 predictions for the future social, economic, and political order, between 9 – 10 March.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005451/en/
The virtual event will host political and industry leaders from around the world, who will each offer their outlooks on the future of vital sectors including healthcare, space, cryptocurrency and more.
Day one will open with a keynote from His Excellency Mohammad Abdullah Al Gergawi, the UAE’s Minister of Cabinet Affairs and Chairman of the World Government Summit Organization, on the priorities for governments in 2021, as they look to navigate the global recovery from the coronavirus (COVID-19) pandemic.
Sessions on day one will focus on the future of Africa, the future of Asia, the future economic order, cryptocurrency and the decentralisation of finance. They will feature Tony Elumelu, Chairman of Heirs Holdings, the United Bank for Africa, Nandan Nilekani, Co-founder of Infosys, Professor Daniel Kahneman, Economics Nobel Prize winner, Anthony Di Iorio, Co-Founder of Ethereum and Jutta Steiner, Co-founder CEO of Parity Technologies, among others.
Day two will open with a keynote address from Dr. Tedros Ghebreyesus, Director-General of the World Health Organization (WHO) where he will outline the future of global public health.
That will be followed by the high-level discussion, “Will the Earth’s Population Be Vaccinated by 2021?”, where His Excellency Macky Sall, President of Senegal, will be joined by Henrietta Fore, Executive Director, UNICEF, His Excellency Sultan Ahmed Bin Sulayem, Group Chairman and CEO, DP World and Dr. David Nabarro, Special Envoy on Covid-19 to the WHO.
A highlight of the second day will see Astrophysicist, Dr. Neil deGrasse Tyson in conversation with the Right Honourable Lord Martin Rees, Astrophysicist, Cosmologist and 60th President of the Royal Society, as they discuss how public-private partnerships can inspire a new generation of STEM enthusiasts to lead the space race and the quest to understand life beyond Earth.
For the full agenda and list of speakers, visit: https://www.worldgovernmentsummit.org/
To register for the event, visit: https://www.worldgovernmentsummit.org/event-registrations/
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005451/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors9.9.2026 15:45:00 CEST | Press release
- Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach – Recognized for realizing a novel drug discovery concept in which a bispecific antibody replaces the function of coagulation Factor VIII, which is deficient in hemophilia A. Provided improved convenience through prolonged activity and subcutaneous administration, and provided a treatment option regardless of factor VIII inhibitors, thereby helping address unmet medical needs in hemophilia A. First time since the establishment of the Lasker Foundation in 1945 that three Japanese researchers have received the award simultaneously. Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been aw
AMCS Appoints Richard Humphrey as Chief Product and Technology Officer9.9.2026 15:00:00 CEST | Press release
Industrial software executive to lead global product strategy and accelerate AI innovation AMCS, a leading technology provider for the waste and recycling industry, today announced the appointment of Richard Humphrey as Chief Product and Technology Officer. Based in Boston, Humphrey will lead the company’s global product organisation. Humphrey brings more than 25 years of experience developing software for construction and other complex industrial environments. He joins AMCS as the company deepens its focus on waste and recycling and expands the role of AI across its platform. Most recently, Humphrey served as Chief Product and Technology Officer at Contruent, where he led product strategy for a construction cost-management platform used on major capital programmes. He previously held vice president roles at Bentley Systems and B2W Software. Earlier in his career, he spent more than a decade at Autodesk, where he led its Civil Design and Construction software business as Senior Directo
BBH Launches a New Technology Business, Braid, Solving for Intelligent Data Transformation9.9.2026 14:45:00 CEST | Press release
Braid’s agentic AI platform is purpose-built for financial services firms who need to transform, connect, and manage their data with confidence Brown Brothers Harriman (BBH) today announced the launch of a new technology affiliate, Braid LLC, focused on solving enterprise data transformation for financial services. Braid offers an AI-native data transformation platform that gives firms a scale solution to transform, connect, and manage their data with confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909294398/en/ Braid empowers teams to build, automate, and oversee reliable production-grade data transformations in a fraction of the time typically required today. Instead of requiring engineers to build data automations, Braid allows business users to describe their needs in natural language that AI agents use to build intelligent data transformations that are transparent and fully auditable. Braid’s enterprise-gr
LTM Collaborates with IBM and Red Hat on Lightwell to Advance AI-Driven Open-Source Software Remediation9.9.2026 14:30:00 CEST | Press release
Strengthens software supply chains by helping enterprises transform vulnerability discovery into scalable remediation outcomes LTM, the Business Creativity partner to the world's largest enterprises, today announced that it has collaborated with IBM and Red Hat on Lightwell to help enterprises safeguard the open-source software supply chain through AI-driven vulnerability remediation. As AI accelerates the discovery of software vulnerabilities, organizations must move beyond detection-focused approaches and adopt enterprise-scale remediation strategies that enable rapid risk mitigation without disrupting business-critical applications. Lightwell’s approach of delivering validated fixes for production environments aligns with LTM's aim of helping customers build secure, resilient, and operationally efficient software supply chains. By combining AI-powered remediation capabilities with enterprise-grade validation and deployment support, Lightwell aims to help organizations address securi
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life9.9.2026 14:24:00 CEST | Press release
Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies Oveporexton is the First and Only Approved Orexin Agonist Designed to Treat the Underlying Cause of NT1 and is Now Approved in the U.S., China and Japan, with Additional Regulatory Submissions Underway Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1. "People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily life,” said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-86
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom